Inappropriate ATAC on tamoxifen

The Lancet Oncology

Volumn 9, Issue 4, 2008, Pages 315-316

  Coates, Alan ^a   Mouridsen, Henning ^b   Thürlimann, Beat ^c  

^a International Breast Cancer Study Group   (Switzerland)

^b Rigshospitalet   (Denmark)

^c Kantonsspital St Gallen   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; HEALTH CARE ORGANIZATION; HUMAN; LETTER; METHODOLOGY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; PROGNOSIS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 41149103890     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70085-8     Document Type: Letter

References (3)

1. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
2. Coates A., Mouridsen H., Mauriac L., and for the BIG 1-98 Collaborative Group. Letrozole or Tamoxifen in early breast cancer. New Engl J Med 354 (2006) 1528-1530
3. United States National Institutes of Health. Comparison trial of letrozole to anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer trial details. http://clinicaltrials.gov/ct2/show/NCT00248170?term=CFEM345D2411&ran k=1 (accessed Jan 18, 2008).